Clinical Trial

Statin Therapy in Patients With Early Stage ADPKD

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study plans to learn if pravastatin is helpful in slowing down the progression of kidney disease in adults with autosomal dominant polycystic kidney disease (ADPKD). Pravastatin has been approved by the Food and Drug Administration (FDA) for adults for treatment of hyperlipidemia (high cholesterol levels). The investigators are using pravastatin in this study as an investigational drug for treatment of ADPKD.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2017-09-01; most recent amendment 2026-06-29.
Status change: Active, Not Recruiting → Completed 2026-02-03
Status change: Recruiting → Active, Not Recruiting 2023-03-13
Trial Details
NCT Number NCT03273413
Lead Sponsor University of Colorado, Denver
Conditions ADPKD, Autosomal Dominant Polycystic Kidney
Enrollment 150 participants
Start Date 2017-08-31
Primary Completion 2024-03-25 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-08